Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)
Prostate Cancer and Prostatic Diseases · 2025-09 · 28 (3) · 652-661
DOI: 10.1038/s41391-024-00901-4 ↗Kurz gefasst
Leitlinie in der Zeitschrift Prostate Cancer and Prostatic Diseases, online erschienen am 01.10.2024. Verfasst von Andrew J Armstrong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University Medical Center, Durham, NC, USA. Hauptthemen laut MEDLINE: Genetic Testing, Prostatic Neoplasms, Castration-Resistant, Precision Medicine, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
BACKGROUND/OBJECTIVES: Unfortunately, not all metastatic castration resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing in prostate cancer. SUBJECTS/METHODS: In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science. RESULTS/CONCLUSION: We argue for the widespread adoption of germline testing in all patients with prostate cancer and for somatic mutations testing in patients at the time of recurrent/metastatic disease. In this first part, we review how genomic testing is performed. We also review how to overcome certain barriers to integrate genetic and biomarker testing into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University Medical Center, Durham, NC, USA.
- University of Wisconsin, Madison, WI, USA.
- Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- City of Hope, Goodyear, AZ, USA.
- The Urology Center of Colorado, Denver, CO, USA.
ORCID-Profile: Andrew J Armstrong, Scott T Tagawa, Anthony V Serritella, Joshua M Lang
Förderung
- NCI NIH HHS
Zitieren
APA
Armstrong, A. J., Taylor, A., Haffner, M. C., Abida, W., Bryce, A. H., Karsh, L. I., Tagawa, S. T., Twardowski, P., Serritella, A. V., & Lang, J. M. (2025). Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2). Prostate Cancer and Prostatic Diseases, 28(3), 652-661. https://doi.org/10.1038/s41391-024-00901-4
Vancouver
Armstrong AJ, Taylor A, Haffner MC, Abida W, Bryce AH, Karsh LI, et al. Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2). Prostate Cancer and Prostatic Diseases. 2025;28(3):652-661. doi:10.1038/s41391-024-00901-4
BibTeX
@article{Armstrong2025,
author = {Armstrong, Andrew J and Taylor, Amy and Haffner, Michael C and Abida, Wassim and Bryce, Alan H and Karsh, Lawrence I and Tagawa, Scott T and Twardowski, Przemyslaw and Serritella, Anthony V and Lang, Joshua M},
title = {Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)},
journal = {Prostate Cancer and Prostatic Diseases},
year = {2025},
volume = {28},
number = {3},
pages = {652--661},
doi = {10.1038/s41391-024-00901-4}
}
EUVIMED